NASDAQ · ZIMV
Healthcare · Medical - Devices
$18.99
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 11:02 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ZIMV does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ZIMV.
ZIMV research
Company profile and research snapshot.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 22, 2025 | Barclays | Equal-Weight | — |
| May 15, 2025 | UBS | Neutral | — |
| Apr 9, 2025 | Needham | Hold | — |
| Mar 13, 2025 | Needham | Hold | — |
| Feb 27, 2025 | Needham | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 20, 2025
ZimVie Inc. has been fully acquired by ARCHIMED, an investment firm focused on healthcare industries. The transaction was completed at $19.00 per share, resulting in ZimVie being delisted from NASDAQ.
Benzinga · Oct 10, 2025
ZimVie stockholders have voted to approve the acquisition by ARCHIMED, with the merger expected to close on October 20, 2025, subject to meeting all agreement conditions.
GlobeNewswire Inc. · Sep 16, 2025
Law firm investigating potential securities law violations and fiduciary duty breaches for ZimVie, Aris Water Solutions, and scPharmaceuticals regarding their proposed sales and merger transactions.
businesswire.com · Sep 16, 2025
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ZimVie Inc. (NasdaqGS: ZIMV) to an affiliate of ARCHIMED. Under the terms of the proposed transaction, shareholders of ZimVie will receive $19.00 in cash for each share of ZimVie that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZIMV.
No results
No recent SID articles mention ZIMV.
